Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer — SPECTRUM  

Recurrent and/or Metastatic Head and Neck Cancer Clinical Trial

Official title: A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the treatment effect of Panitumumab in combination with chemotherapy versus chemotherapy alone as first line therapy for metastatic and/or recurrent squamous cell carcinoma of the head and neck.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Head and Neck Neoplasms
• Recurrent and/or Metastatic Head and Neck Cancer

• NCT number: NCT00460265
• Study type: Interventional
• Source: Amgen
• Status: Completed
• Phase: Phase 3
• Start date: May 2007
• Completion date: May 2012